Research programme: anticancer antibodies - Patrys
Alternative Names: 3E10; 5C6; 5C6 antibody; Deoxymab; Deoxymab 3E10; Deoxymab-1; PAT-BA1; PAT-BA2; PAT-BA4; PAT-CM1; PAT-NM1; PAT-NM2; PAT-PM1; PAT-PM2; PAT-SM3; PAT-SM4; PAT-SM5Latest Information Update: 28 Jan 2022
At a glance
- Originator OncoMab GmbH; Patrys; Yale University
- Developer Patrys; Yale University
- Class Antibodies; Antineoplastics; Monoclonal antibodies
- Mechanism of Action Cell death stimulants; DNA repair inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer